David Mott, Ten Percent Owner at Arca Biopharma, holds 598.29K shares in Mersana Therapeutics (Ticker: MRSN), holds 1.19M shares in Ardelyx (Ticker: ARDX), holds 43.80K shares in Novavax (Ticker: NVAX).
David Mott latest transaction was an Uninformative Buy of ―.
What was David Mott's most profitable transaction?
David Mott’s most profitable transaction was an Informative Buy of AKAOQ stock on June 7, 2016. The return on the trade was 423.70%.
What is David Mott's role in Arca Biopharma?
David Mott's role in Arca Biopharma is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.